Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas

Area of Science:

• Neuro-oncology
• Genomics
• Proteomics

Background:

• Meningioma is a prevalent primary central nervous system tumor causing significant patient burden.
• Current pharmacological treatments for meningioma are limited.
• There is a need for novel therapeutic targets.

Purpose of the Study:

• To identify potential therapeutic targets for meningioma.
• To integrate multi-omics data for target discovery.
• To provide insights for targeted meningioma therapy development.

Main Methods:

• Integrated meningioma data from UK Biobank and Finnish databases.
• Employed bioinformatics and Mendelian randomization for multi-omics analysis.
• Utilized phenotype-wide association group analysis for target evaluation.

Main Results:

• Identified ten potential therapeutic targets: BET1L, COL17A1, CFAP43, SH3PXD2A, TTC28, ZNRF3, SLK, AKR1C3, NRXN3, and RSPO3.
• These genes represent novel candidates for meningioma drug development.
• Demonstrated the biological significance of these targets.

Conclusions:

• This study provides evidence for ten novel therapeutic targets in meningioma.
• Highlights the potential of BET1L, COL17A1, and others in targeted therapy.
• Offers new insights for developing advanced meningioma treatments.